Investigational Treatments for Hidradenitis Suppurativa

Recruiting in Palo Alto (17 mi)

+46 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Novartis Pharmaceuticals

Prior Safety Data

Trial Summary

What is the purpose of this trial?The main purpose of this study is to assess preliminary efficacy and safety of CFZ533, LYS006, MAS825 , LOU064 and VAY736 in patients with moderate to severe hidradenitis suppurativa and to determine if CFZ533, LYS006, MAS825, LOU064 and VAY736 have an adequate clinical profile for further clinical development.

Eligibility Criteria

This trial is for individuals over 50 kg with moderate to severe Hidradenitis Suppurativa. Participants must be able to follow the study's procedures and visit schedule. Pregnant or breastfeeding women, or those who can become pregnant and are not using effective contraception, cannot join.

Inclusion Criteria

I have moderate to severe HS with many lesions or fistulae.

I weigh at least 50 kg.

Able to communicate well with the investigator and understand and comply with the requirements of the study, and the ability and willingness to conduct study visits as per the study schedule

Exclusion Criteria

Other protocol-defined inclusion/exclusion criteria may apply

Pregnant or lactating women

I am using reliable birth control methods.

+1 more

Participant Groups

The trial is testing the effectiveness and safety of several potential treatments: CFZ533, LYS006, MAS825, LOU064 (in two doses), and VAY736 against placebos. The goal is to see if these drugs should be developed further for treating Hidradenitis Suppurativa.

11Treatment groups

Experimental Treatment

Active Control

Placebo Group

Group I: VAY736Experimental Treatment1 Intervention

s.c.

Group II: MAS825Experimental Treatment1 Intervention

s.c.

Group III: LYS006Experimental Treatment1 Intervention

p.o.

Group IV: CFZ533Experimental Treatment1 Intervention

s.c.